UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer

PloS one, 2020-07, Vol.15 (7), p.e0235705

2020

Volltextzugriff (PDF)

Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A -Mutated Advanced Urothelial Carcinoma

Molecular cancer therapeutics, 2019-01, Vol.18 (1), p.185-195

2019

Volltextzugriff (PDF)

897-G SR-8541A, a small molecule inhibitor of ENPP1, enhances the effect of immune checkpoint inhibitors in a colorectal cancer model

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 2), p.A1826-A1826

2023

Volltextzugriff (PDF)

Abstract 1175: Identification of novel combination therapies with the LSD1 inhibitor SP-2577 (Seclidemstat) in Ewing's Sarcoma using a complete druggable CRISPR library approach

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1175-1175

2021

Volltextzugriff (PDF)

Abstract LB-107: Targeting CDK7-dependent transcriptional addiction with novel, orally available small molecule inhibitor shows efficacy in pancreatic cancer models

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.LB-107-LB-107

2019

Volltextzugriff (PDF)

Abstract 3869: The reversible LSD1 inhibitor SP-2509 promotes anti-tumor immunity in small cell carcinoma of the ovary-hypercalcemic type (SCCOHT)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3869-3869

2019

Volltextzugriff (PDF)

Abstract LB-118: SR8541A is a potent inhibitor of ENPP1 and exhibits dendritic cell mediated antitumor activity

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.LB-118-LB-118

2020

Volltextzugriff (PDF)

Abstract 1254: Preclinical studies with TGN-1062, a selective and reversible small molecule inhibitor of CDK7

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1254-1254

2021

Volltextzugriff (PDF)

Abstract 3068: Everolimus mediated Radioprotection on surrounding healthy tissue in glioblastoma microbrain models

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.3068-3068

2021

Volltextzugriff (PDF)

Abstract 1932: Discovery of ENPP1 inhibitors as agonists of STING pathway

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1932-1932

2018

Volltextzugriff (PDF)

Abstract 3077: Preclinical studies of SR-8314, a highly selective ENPP1 inhibitor and an activator of STING pathway

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3077-3077

2019

Volltextzugriff (PDF)

Abstract 5221: Development of TGN-1076, a selective and reversible small molecule inhibitor of CDK7

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5221-5221

2020

Volltextzugriff (PDF)

Abstract 6681: Inhibition of LSD1 using the reversible inhibitor SP2577 promotes Interferon dependent anti-tumor response in adrenocortical carcinoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6681-6681

2020

Volltextzugriff (PDF)

The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin β -Like 1- β -Catenin Protein Complex

The Journal of pharmacology and experimental therapeutics, 2021-08, Vol.378 (2), p.77-86

2021

Volltextzugriff (PDF)

Abstract 96: Effect of LSD-1 inhibition on docetaxel resistance in prostate cancer cells

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.96-96

2015

Volltextzugriff (PDF)

Abstract C91: Reversible lysine specific demethylase-1 inhibition is synergistic with docetaxel in castrate refractory prostate cancer

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.C91-C91

2015

Volltextzugriff (PDF)

Abstract CT161: First-in-human study of ENPP1 inhibitor, SR-8541A, for the treatment of solid tumors

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT161-CT161

2024

Volltextzugriff (PDF)

GFI1B Splice Variants Differentially Regulate Transcription and Megakaryocyte/Erythrocyte Fate in Hematopoiesis

Blood, 2017-12, Vol.130, p.2430-2430

2017

Volltextzugriff (PDF)

Abstract 671: G-protein coupled receptor (GPCR) screening library identifies sertindole, an antipsychotic, as potential therapeutic option to target GNAQ mutation Q209L in uveal melanoma

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.671-671

2024

Volltextzugriff (PDF)

Abstract 607: Development of a novel, selective, and potent inhibitor of RON kinase

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.607-607

2024

Volltextzugriff (PDF)

Abstract 4404: PAThway based RNA and DNA Integration with tumor Organoid Testing for clinical therapeutics (PATRIOT)

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4404-4404

2020

Volltextzugriff (PDF)

Abstract LB323: Inhibition of ENPP1 using small molecule, SR-8541A, enhances the effect of checkpoint inhibition in cancer models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB323-LB323

2023

Volltextzugriff (PDF)

Abstract 1666: Novel peptides target the β-catenin/TBL1 complex to competitively inhibit dysregulated Wnt signaling in cancer

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1666-1666

2023

Volltextzugriff (PDF)

Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC)

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.379-379

2017

Volltextzugriff (PDF)

Abstract 5718: TGN-1062, a dual CDK7 and FLT3 Inhibitor, shows potent anti-AML activity and synergizes with Venetoclax

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.5718-5718

2024

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(53)
Buchkapitel
(1)

Sprache

Englisch
(54)

Erscheinungsjahr

n.n

Thema

Science & Technology
(14)
Life Sciences & Biomedicine
(10)
Humans
(6)
Cell Line, Tumor
(4)
Tumors
(4)
Cell Cycle
(3)
Covid-19
(3)
Metastases
(3)
631/80/641/2350
(2)
Antineoplastic Agents - Pharmacology
(2)
Biochemistry & Molecular Biology
(2)
Biomedical And Life Sciences
(2)
Biomedicine
(2)
Cancer
(2)
Cancer Therapies
(2)
Cell Cycle Checkpoints
(2)
Cell Division
(2)
Computer Science Education
(2)
Computing
(2)
Disproportionate Representation
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer

Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A -Mutated Advanced Urothelial Carcinoma

897-G SR-8541A, a small molecule inhibitor of ENPP1, enhances the effect of immune checkpoint inhibitors in a colorectal cancer model

Abstract 1175: Identification of novel combination therapies with the LSD1 inhibitor SP-2577 (Seclidemstat) in Ewing's Sarcoma using a complete druggable CRISPR library approach

Abstract LB-107: Targeting CDK7-dependent transcriptional addiction with novel, orally available small molecule inhibitor shows efficacy in pancreatic cancer models

Abstract 3869: The reversible LSD1 inhibitor SP-2509 promotes anti-tumor immunity in small cell carcinoma of the ovary-hypercalcemic type (SCCOHT)

Abstract LB-118: SR8541A is a potent inhibitor of ENPP1 and exhibits dendritic cell mediated antitumor activity

Abstract 1254: Preclinical studies with TGN-1062, a selective and reversible small molecule inhibitor of CDK7

Abstract 3068: Everolimus mediated Radioprotection on surrounding healthy tissue in glioblastoma microbrain models

Abstract 1932: Discovery of ENPP1 inhibitors as agonists of STING pathway

Abstract 3077: Preclinical studies of SR-8314, a highly selective ENPP1 inhibitor and an activator of STING pathway

Abstract 5221: Development of TGN-1076, a selective and reversible small molecule inhibitor of CDK7

Abstract 6681: Inhibition of LSD1 using the reversible inhibitor SP2577 promotes Interferon dependent anti-tumor response in adrenocortical carcinoma

The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin β -Like 1- β -Catenin Protein Complex

Abstract 96: Effect of LSD-1 inhibition on docetaxel resistance in prostate cancer cells

Abstract C91: Reversible lysine specific demethylase-1 inhibition is synergistic with docetaxel in castrate refractory prostate cancer

Abstract CT161: First-in-human study of ENPP1 inhibitor, SR-8541A, for the treatment of solid tumors

GFI1B Splice Variants Differentially Regulate Transcription and Megakaryocyte/Erythrocyte Fate in Hematopoiesis

Abstract 671: G-protein coupled receptor (GPCR) screening library identifies sertindole, an antipsychotic, as potential therapeutic option to target GNAQ mutation Q209L in uveal melanoma

Abstract 607: Development of a novel, selective, and potent inhibitor of RON kinase

Abstract 4404: PAThway based RNA and DNA Integration with tumor Organoid Testing for clinical therapeutics (PATRIOT)

Abstract LB323: Inhibition of ENPP1 using small molecule, SR-8541A, enhances the effect of checkpoint inhibition in cancer models

Abstract 1666: Novel peptides target the β-catenin/TBL1 complex to competitively inhibit dysregulated Wnt signaling in cancer

Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC)

Abstract 5718: TGN-1062, a dual CDK7 and FLT3 Inhibitor, shows potent anti-AML activity and synergizes with Venetoclax

Suchergebnisse filtern